Biocartis

Biocartis

High precision diagnostics for personalized medicine

Founded 2007 Belgium

Belgium 314 employees Grant Total: $322.90M Biotechnology, Health Care +1

Biocartis is a Belgian-based biotechnology startup founded in 2007 with a mission to revolutionize the field of molecular diagnostics. The company's slogan "High precision diagnostics for personalized medicine" encapsulates its focus on providing next generation diagnostic solutions for personalized medicine. Biocartis has gained significant attention in the industry due to its proprietary MDx Idylla™ platform, a fully automated, real-time system that offers accurate and highly reliable molecular information from any biological sample in virtually any setting. With a recent €1.20M grant investment at 30 September 2020 from Agentschap Innoveren & Ondernemen, Biocartis is advancing its efforts to address key unmet clinical needs, particularly in the oncology and infectious diseases segments. These areas represent the fastest and largest growing segments of the US$6.5 billion molecular diagnostics market, positioning Biocartis as a key player in this rapidly evolving industry. By employing over 500 individuals, Biocartis has established its headquarters in Mechelen, Belgium. The company's vision is to enable universal access to molecular testing, with a focus on making molecular testing actionable, convenient, fast, and suitable for any lab. With its innovative approach and focus on personalized medicine, Biocartis is well positioned to drive significant impact in the healthcare and biotechnology sectors. For further information about Biocartis, interested parties can visit www.biocartis.com.

Funding Stage	Amount	Investors	Lead Investors	Date
Grant	€1.20M	1	Agentschap Innoveren & Ondernemen	30 Sep 2020
Post IPO Equity	€80.00M	-		28 Nov 2017
Series F	€64.50M	3	Johnson & Johnson Development Corporation, PMV Tina Fund +1	04 Sep 2014
Grant	€1.70M	-		26 Jun 2014
Series E	€30.00M	8	Wellcome Trust, Debiopharm Innovation Fund +6	05 Nov 2013
Series D	€34.50M	10	New Rhein Healthcare Investors, Valiance Advisors +8	12 Dec 2012
Series C	€71.00M	3	Wellcome Trust, Johnson & Johnson Development Corporation +1	17 Nov 2011
Series B	€30.00M	5	Advent Venture Partners, Aescap Venture +3	08 Apr 2010
Series A	€10.00M	2	Advent Venture Partners, Aescap Venture	15 Oct 2009

Funding Stage

Amount

Investors

Lead Investors

Date

Grant

€1.20M

Agentschap Innoveren & Ondernemen

30 Sep 2020

Post IPO Equity

€80.00M

28 Nov 2017

Series F

€64.50M

Johnson & Johnson Development Corporation, PMV Tina Fund +1

04 Sep 2014

Grant

€1.70M

26 Jun 2014

Series E

€30.00M

Wellcome Trust, Debiopharm Innovation Fund +6

05 Nov 2013

Series D

€34.50M

New Rhein Healthcare Investors, Valiance Advisors +8

12 Dec 2012

Series C

€71.00M

Wellcome Trust, Johnson & Johnson Development Corporation +1

17 Nov 2011

Series B

€30.00M

Advent Venture Partners, Aescap Venture +3

08 Apr 2010

Series A

€10.00M

Advent Venture Partners, Aescap Venture

15 Oct 2009

FAQ About Biocartis

High precision diagnostics for personalized medicine

Biocartis was founded in 2007.

Biocartis is headquartered in Belgium. As of Sep 2026, it also has offices in Mechelen, Belgium and Itasca, United States.

Biocartis operates in Biotechnology, Health Care and Medical Devices. Its work centres on molecular diagnostics, personalized medicine, oncology and infectious diseases.

Biocartis has approximately 314 employees.

Biocartis has completed 9 funding rounds, raising a total of $322.90M. The latest funding stage is Grant.

Top alternatives and competitors to Biocartis include ACT Genomics, OncoDNA, Selah Genomics Inc, Invivoscribe, CY Molecular Diagnostics (CYMD). These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Biocartis and ACT Genomics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Biocartis

Funding Rounds & Investors (9)

Biocartis Alternatives & Competitors

FAQ About Biocartis